Jason Coppell

Exeter, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real-World Management of Myeloproliferative Neoplasms.

Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real-World Management of Myeloproliferative Neoplasms.

Journal: EJHaem

Published: December 20, 2024

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 01, 2023

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.

Journal: Nature communications

Published: March 13, 2023

An open-source, expert-designed decision tree application to support accurate diagnosis of myeloid malignancies.

An open-source, expert-designed decision tree application to support accurate diagnosis of myeloid malignancies.

Journal: EJHaem

Published: February 16, 2021

The Use of Tranexamic Acid to Reduce the Need for Nasal Packing in Epistaxis (NoPAC): Randomized Controlled Trial.

The Use of Tranexamic Acid to Reduce the Need for Nasal Packing in Epistaxis (NoPAC): Randomized Controlled Trial.

Journal: Annals of emergency medicine

Published: February 10, 2020

Novel use of tranexamic acid to reduce the need for Nasal Packing in Epistaxis (NoPac) randomised controlled trial: research protocol.

Novel use of tranexamic acid to reduce the need for Nasal Packing in Epistaxis (NoPac) randomised controlled trial: research protocol.

Journal: BMJ open

Published: February 18, 2019

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Journal: Blood

Published: May 24, 2017

Discrepancy in von Willebrand factor activity determined by ristocetin cofactor and immunotubidometric assays.

Discrepancy in von Willebrand factor activity determined by ristocetin cofactor and immunotubidometric assays.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: March 19, 2014

Showing 1-8 of 8

Last Updated: 09/26/2026